Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Immune Surveillance by NK Cells and Phagocytes01:25

Immune Surveillance by NK Cells and Phagocytes

Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats.
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic and functional analysis including repetitive antigen stimulation provides a more accurate assessment for CAR-T cell product quality and long-term functionality.

Journal of translational medicine·2026
Same author

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same author

A 3-year-old girl with a left optic nerve tumor.

Brain pathology (Zurich, Switzerland)·2026
Same author

Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across Europe.

JCO global oncology·2026
Same author

Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer.

NPJ breast cancer·2026
Same author

Tumor ecology and the paradox of clean margins in multicentric breast cancer: an exploratory organoid-based functional study.

Breast cancer research : BCR·2026

Related Experiment Video

Updated: Jun 24, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review.

Jesús Peña-López1, Angelo Gámez-Pozo2,3, Lucía Trilla-Fuertes2

  • 1Medical Oncology Department, Hospital Universitario La Paz, Universidad Autónoma, 28046 Madrid, Spain.

International Journal of Molecular Sciences
|February 27, 2026
PubMed
Summary

The NKG2D/NKG2D ligand (NKG2DL) axis is expressed in breast cancer (BC) tissues, but its association with patient outcomes is weak. Resistance mechanisms may limit the effectiveness of targeting this axis in BC immunotherapy.

Keywords:
NKG2DNKG2DLbreast cancerin silico

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.0K

Related Experiment Videos

Last Updated: Jun 24, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.0K

Area of Science:

  • Immunology
  • Oncology
  • Genomics

Background:

  • Breast cancer (BC) is a heterogeneous disease requiring novel immunotherapies, especially for metastatic cases.
  • The NKG2D/NKG2D ligand (NKG2DL) axis is crucial for innate antitumor immunity but its role in BC is not fully understood.

Purpose of the Study:

  • To investigate the expression and clinical relevance of the NKG2D/NKG2DL axis in breast cancer.
  • To explore potential therapeutic strategies targeting this axis.

Main Methods:

  • In silico analysis of NKG2DL expression using transcriptomic databases (e.g., GTEx, TCGA).
  • Survival analyses utilizing TCGA and KMPlot data.
  • Narrative literature review on NKG2DL expression and immunotherapy resistance mechanisms.

Main Results:

  • NKG2DL transcripts were consistently found in BC cell lines and tumor tissues, with higher expression in ductal histology, advanced stage, and basal subtype.
  • Survival analyses revealed generally weak and heterogeneous associations between individual NKG2DLs and clinical outcomes.
  • Literature review indicated NKG2DL expression in tumors but not healthy tissues, alongside effector cell dysfunction and resistance mechanisms like ligand shedding.

Conclusions:

  • The NKG2D/NKG2DL axis is expressed in breast cancer, but its direct correlation with prognosis is limited.
  • Understanding resistance mechanisms is critical for developing effective immunotherapies targeting the NKG2D/NKG2DL pathway in BC.